Feb 14 (Reuters) - Johnson & Johnson ( JNJ ) said on
Friday it has resumed the limited market release of its
Varipulse heart device in the United States after an
investigation found the devices operate as intended.
In January, the company had paused the heart device, a
pulsed field ablation system, citing an abundance of caution as
it investigated four reported stroke events.